March 19-20, 2014
Omni Parker House, Boston, MA
Mitochondrial dysfunction has been identified as an important factor in diseases ranging from neurodegenerative conditions (ALS, Alzheimer's, Parkinson's Disease), epilepsy, psychiatric illness and autism, to cardiovascular disease, liver/kidney disease, diabetes and cancer. The wide-ranging impact of mitochondria in so many diseases makes them prime targets for therapeutics.
Additionally, medications for many diseases cause unwanted toxicity to the mitochondria. Mitochondrial toxicity is one of the leading causes of attrition in the drug development process, as well as in post-market drug withdrawals. Targeting Mitochondrial Dysfunction & Toxicity (the first conference of its kind in the US) will present the latest research in new targeting pathways, novel therapeutics, and methods to decrease or eliminate mitochondrial toxicity when developing therapeutics for many indications.